Antares Pharma, Inc. (ATRS) Receives Consensus Rating of “Buy” from Analysts
Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have been given an average recommendation of “Buy” by the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.43.
Several research analysts recently commented on the stock. Chardan Capital began coverage on shares of Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a report on Sunday, September 10th. Vetr raised shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 target price on the stock in a report on Tuesday, July 18th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th.
Several institutional investors and hedge funds have recently made changes to their positions in ATRS. Asymmetry Capital Management L.P. purchased a new stake in shares of Antares Pharma in the second quarter worth about $643,000. California State Teachers Retirement System bought a new position in shares of Antares Pharma in the second quarter valued at approximately $820,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Antares Pharma in the second quarter valued at approximately $307,000. The Manufacturers Life Insurance Company boosted its position in shares of Antares Pharma by 1,188.2% in the second quarter. The Manufacturers Life Insurance Company now owns 121,633 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 112,191 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Antares Pharma in the second quarter valued at approximately $174,000. Hedge funds and other institutional investors own 36.77% of the company’s stock.
Antares Pharma (NASDAQ ATRS) opened at 3.63 on Wednesday. The firm’s 50-day moving average price is $3.07 and its 200-day moving average price is $2.95. Antares Pharma has a 1-year low of $1.41 and a 1-year high of $3.73. The company’s market cap is $567.76 million.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Equities research analysts forecast that Antares Pharma will post ($0.11) EPS for the current fiscal year.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.